ClinicalTrials.gg
Drug

Nerandomilast clinical trials

Also written JASCAYD® and BI 1015550.

studies test it
36
open now
7
in phase 3
9
first study started
2012

How each study uses nerandomilast is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the nerandomilast studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
7 Oct 2025 · JASCAYD · NDA 218764 (FDA, Drugs@FDA)
European Union
15 Jul 2026 · Jascayd · EMEA/H/C/006405 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Nerandomilast
26
BI 1015550, JASCAYD®
3
Nerandomilast, JASCAYD®
3
Nerandomilast 18 mg - adult formulation
2

Brand

JASCAYD®
21

Development codes

BI 1015550
20

Studies by the year they started

36 studies that test it; most in 2024 (7)

Studies that test nerandomilast, by start year
YearStudies
20121
20131
20172
20183
20201
20211
20224
20236
20247
20253
20267

By phase

A phase 1/2 study counts in both.

Phase 1
23
Phase 2
4
Phase 3
9
Phase 4
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 34 · Other 2

Boehringer Ingelheim (33) · University of British Columbia (1) · Gipfel Life Sciences GmbH (1) · Scleroderma Research Foundation, Inc. (1)

Often tested with

Tested in the same studies.

Pirfenidone (2) · Nintedanib (1) · Carbamazepine (1) · Bosentan (1) · BI 101550 (1) · LY-2157299 (1) · Amlitelimab (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 5, 3 in phase 3

Studies that test nerandomilast, phase 3 first.

Studies

Open first, then newest update. How each study uses nerandomilast is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 36

See all 36 studies that test nerandomilast →

Codes

What other systems call nerandomilast · ClinicalTrials.gg INT002017

  • MeSH (NLM) C000727475nerandomilastConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) I5DGT51IB8NERANDOMILASTConfirmed FDA, NLM
  • NCI Thesaurus C203229NerandomilastOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.